These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31315664)

  • 1. Proteome profiling of low grade serous ovarian cancer.
    Zadeh Fakhar HB; Zali H; Rezaie-Tavirani M; Darkhaneh RF; Babaabasi B
    J Ovarian Res; 2019 Jul; 12(1):64. PubMed ID: 31315664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analyses of serous and endometrioid epithelial ovarian cancers - cases studies - molecular insights of a possible histological etiology of serous ovarian cancer.
    Longuespée R; Gagnon H; Boyon C; Strupat K; Dauly C; Kerdraon O; Ighodaro A; Desmons A; Dupuis J; Wisztorski M; Vinatier D; Fournier I; Day R; Salzet M
    Proteomics Clin Appl; 2013 Jun; 7(5-6):337-54. PubMed ID: 23589350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-assessment of the high-grade serous ovarian cancer phosphoproteome - Identification of kinase candidates in TCGA tumors for future clinical intervention.
    Rolfs F; Piersma SR; Jimenez CR
    EBioMedicine; 2019 Mar; 41():34-35. PubMed ID: 30797713
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low-grade serous carcinoma.
    Vallejos R; Zhantuyakova A; Negri GL; Martin SD; Spencer SE; Thornton S; Leung S; Lynch B; Qin Y; Chow C; Liang B; Zdravko S; Douglas JM; Milne K; Mateyko B; Nelson BH; Howitt BE; Kommoss FK; Horn LC; Hoang L; Singh N; Morin GB; Huntsman DG; Cochrane D
    J Pathol; 2024 Oct; 264(2):197-211. PubMed ID: 39081243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.
    Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG
    Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX; Yu L; Bi R; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.
    Xie H; Wang W; Sun F; Deng K; Lu X; Liu H; Zhao W; Zhang Y; Zhou X; Li K; Hou Y
    Sci Rep; 2017 Aug; 7(1):9896. PubMed ID: 28852147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients.
    Gayarre J; Kamieniak MM; Cazorla-Jiménez A; Muñoz-Repeto I; Borrego S; García-Donas J; Hernando S; Robles-Díaz L; García-Bueno JM; Ramón Y Cajal T; Hernández-Agudo E; Heredia Soto V; Márquez-Rodas I; Echarri MJ; Lacambra-Calvet C; Sáez R; Cusidó M; Redondo A; Paz-Ares L; Hardisson D; Mendiola M; Palacios J; Benítez J; García MJ
    J Gynecol Oncol; 2016 Jan; 27(1):e7. PubMed ID: 26463438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 10. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade.
    Pan Y; Jiao J; Zhou C; Cheng Q; Hu Y; Chen H
    Pathobiology; 2010; 77(6):283-8. PubMed ID: 21266826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
    Chen X; Wang X; Wei X; Wang J
    J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycodelin in ovarian serous carcinoma: association with differentiation and survival.
    Mandelin E; Lassus H; Seppälä M; Leminen A; Gustafsson JA; Cheng G; Bützow R; Koistinen R
    Cancer Res; 2003 Oct; 63(19):6258-64. PubMed ID: 14559812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.
    Hughes CS; McConechy MK; Cochrane DR; Nazeran T; Karnezis AN; Huntsman DG; Morin GB
    Sci Rep; 2016 Oct; 6():34949. PubMed ID: 27713570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
    Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
    Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
    Zhang J; Wang JC; Li YH; Wang RX; Fan XM
    Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell-Related Marker NANOG Expression in Ovarian Serous Tumors: A Clinicopathological Study of 159 Cases.
    Kenda Šuster N; Frković Grazio S; Virant-Klun I; Verdenik I; Smrkolj Š
    Int J Gynecol Cancer; 2017 Nov; 27(9):2006-2013. PubMed ID: 28906309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.